CN105055892A - Pharmaceutical composition for treating pulmonary heart disease - Google Patents
Pharmaceutical composition for treating pulmonary heart disease Download PDFInfo
- Publication number
- CN105055892A CN105055892A CN201510572029.1A CN201510572029A CN105055892A CN 105055892 A CN105055892 A CN 105055892A CN 201510572029 A CN201510572029 A CN 201510572029A CN 105055892 A CN105055892 A CN 105055892A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- pharmaceutical composition
- heart disease
- extract
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Abstract
The invention discloses a pharmaceutical composition for treating a pulmonary heart disease and a preparation method thereof. The pharmaceutical composition for treating the pulmonary heart disease is prepared from bulk pharmaceutical chemicals, namely berberis heteropoda, almond, central Asia rhizoma bletillae, eoixol, nardosinone and soladulcidine, can be prepared into various dosage forms by adopting the conventional preparation technology and has an obvious pulmonary heart disease curative effect.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition for the treatment of pulmonary heart disease and preparation method thereof.
Background technology
Chronic pulmonary heart disease (chronicpulmonaryheartdisease) is called for short pulmonary heart disease (chroniccorpulmonale), it is a kind of commonly encountered diseases of respiratory system, pathological changes because of Bronchi-pulmonary tissue, blood vessel or thorax causes pulmonary vascular resistance to increase, produce pulmonary hypertension, and then a kind of disease causing the change of right ventricle structure and (or) function (1).The change of major effect cardio-pulmonary function, also can cause the pathological changes of whole body.The prevalence of the National survey report display pulmonary heart disease of eighties of last century the seventies is about 0.5%, case fatality rate is 15%, and the Patients With Cor Pulmonale of about 85% is with when arrhythmia to the nineties, the prevalence of Central China and this disease of northern territory is but up to 3%, occupy China's mortality first three, scorching by chronic bronchitis at the most chronic pulmonary heart disease of China, chronic obstructive pulmonary disease develops, and along with present atmospheric pollution is serious, chronic bronchitis is scorching, the prevalence of chronic obstructive pulmonary disease is more and more higher, therefore the prevalence being not difficult to infer chronic pulmonary heart disease also will be more and more higher.So high sickness rate, the course of disease is long, repeatedly falls ill, and is usually to be brought out by respiratory tract infection.This not only adds the misery of patient, the medical insurance of Ye Shi China increases heavy financial burden.Current western medical treatment pulmonary heart disease still achieves reasonable curative effect, but be but very easy to lead to complications, such as: acid base imbalance, electrolyte disturbance, superinfection, lung heart and brain are sick, digestive tract hemorrhage, shock, renal failure etc. develop the cardio-pulmonary function of patient worse and worse thus, and the ability of oneself's life also worse and worse, will bring white elephant to family.
Kakonein belongs to the categories such as traditional Chinese medical science pulmonary distension, phlegm retention, edema.Be multiple chronic lung pattern disease repeatedly protracted course of disease cause lung qi distension, a kind of disease of falling can not be held back.Main manifestations is positive QI-insufficiency, impaired depurative descending of lung QI, can not spreading essence of water and grain, and poly-liquid is expectorant; Expectorant is turbid stays for a long time, lung qi stasis, and it is the stasis of blood that heart arteries and veins loses smooth then blood stagnation.With the passing of time, damage lung qi, pneumonopathy and kidney, lung insufficiency of kidney-YANG can not evaporate water liquid and spread unchecked skin the expectorant stasis of blood, the heart attacked by pathogenic water, stagnation of heart-blood.Expectorant stasis of blood volt lung, reciprocal causation, causes cause and effect vicious cycle.Generally early stage turbid based on expectorant, the gradually expectorant stasis of blood seeing, blood stasis, diseases caused by retention of fluid turbid to expectorant are mixed for suffering from eventually.Therefore, expectorant stasis of blood volt lung is its basic pathogenesis.And expectorant turbid be YIN pathogen, non-Wen Buhua.Therefore warming YANG to promote diuresis, dissipating phlegm and removing blood stasis are its basic therapies.
Radix Berberidis Amurensis fruit: this product is the dry mature fruit of Berberidaceae plant Berberis nummularia Bge. BerberisnummulariaBge..Its property put down, have stomach invigorating and in, promoting the production of body fluid to quench thirst, effect of heat-clearing and toxic substances removing.For dyspepsia, under dysentery is rushed down, thirsty, aphtha, pharyngitis.
Semen Armeniacae Dulcis: this product is the dry mature seed of rosaceous plant sweet bar dawn AmygdaluscommunisL..During autumn in summer fruit maturation, gather and get core, dry.Used time is except decapsidate.One-level is damp and hot.Have to help and protect trophicity, keep fit brain-strengthening, improving eyesight skin care, effect of intestine moistening cough-relieving, for physical weakness, cough ant phlegm, constipation uncomfortable in chest, poor or weak eyesight breadboard.
Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae), this product is the dry tuber of orchid helmet Herba Orchidis Latifoliae OrchismorioL., Bears Herba Orchidis Latifoliae OrchismasculaL., variegated leaf Herba Orchidis Latifoliae OrchismaculateL., the blue OrchischloranthaGust. of LVHUA tongue lip etc.Xia Qiu excavates, removing impurity, and put a moment in boiling water, taking-up is dried.Character, secondary is damp and hot.There is tonifying YANG spermatogenesis, the effect of the hemopoietic that nourishes heart.For the weak premature ejaculation of sun, refreshing tired insufficiency of blood, oligospermia is infertile, and human body is twitched, and paralysis is dull-witted, alopecia, difference of sleeping.
Coixol (coixol): CAS 532-91-2, molecular formula C
8h
7nO
3, molecular weight 165.14.
Nardosinone (Nardosinone): CAS 23720-80-1, molecular formula C
15h
22o
3, molecular weight 250.33.
Megacarpidine (soladulcidine): also known as soladulcine.CAS 511-98-8, molecular formula C
27h
45nO
2, molecular weight 415.66, fusing point 209 ~ 211 DEG C.Optical rotation [α]
d-50 ° (c=0.4, chloroform).Naturally to be present in the plants such as the fruit of plant of Solanaceae Fructus Solani Dulcamarae (Herba Solani Lyrati, bittersweet) (SolanumdulcamaraL.).There is antifungic action.Inhibit activities is had to Clavicipitaceae, Pyricularia oryzae etc.;
Nardosinone (Nardosinone) megacarpidine (soladulcidine)
Coixol (coixol).
Summary of the invention
The object of the invention is the deficiency overcoming background technology, pharmaceutical composition of a kind of effective treatment pulmonary heart disease and preparation method thereof is provided.
The present invention adopts following technical scheme to realize:
Composition and the weight portion of making the crude drug of the pharmaceutical composition of this treatment pulmonary heart disease are:
Radix Berberidis Amurensis fruit 50-60 weight portion Semen Armeniacae Dulcis 100-110 weight portion Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) 30-40 weight portion Coixol 20-30 weight portion nardosinone 6-8 weight portion megacarpidine 3-5 weight portion.
Preferably be used for the treatment of the pharmaceutical composition of pulmonary heart disease, be made up of the crude drug of following weight portion:
Radix Berberidis Amurensis fruit 55 weight portion Semen Armeniacae Dulcis 105 weight portion Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) 35 weight portion Coixol 25 weight portion nardosinone 7 weight portion megacarpidine 4 weight portions.
Treat a pharmaceutical composition for pulmonary heart disease, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet, capsule, drop pill.
Treat a pharmaceutical composition for pulmonary heart disease, it is characterized in that the treatment pulmonary heart disease medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
Treat a preparation method for the pharmaceutical composition of pulmonary heart disease, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Radix Berberidis Amurensis fruit 50-60 weight portion Semen Armeniacae Dulcis 100-110 weight portion Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) 30-40 weight portion Coixol 20-30 weight portion nardosinone 6-8 weight portion megacarpidine 3-5 weight portion;
Preparation method:
(1) get Semen Armeniacae Dulcis, Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) by crude drug proportioning, mixing, first uses weight percent concentration 90% ethanol as solvent, extract at 55 DEG C of warm macerating, extraction time is 4 times, and each extraction time is 3 hours, each solvent load be Semen Armeniacae Dulcis, 20 times of Central Asia Bletilla striata medicinal materials gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, concentrated, drying, obtains extract A;
(2) Radix Berberidis Amurensis fruit is got by crude drug proportioning, and obtain medicinal residues A with step (1) and mix, be solvent with weight percent concentration 55% ethanol, extract at 70 DEG C of warm macerating, extraction time is 3 times, each extraction time is 3 hours, each solvent load is 15 times of above-mentioned medical material gross weight, filter, extracting solution reclaims ethanol, be concentrated into relative density 1.06, filter, medicinal liquid is by HPD600 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting HPD600 macroporous adsorptive resins of weight percent concentration 75% again, collect weight percent concentration 75% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) get Coixol, nardosinone, megacarpidine by crude drug proportioning, mixing, adds extract A, extract B successively, and mixing, obtains pharmaceutical composition.
Preferably treat a preparation method for the pharmaceutical composition of pulmonary heart disease, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Radix Berberidis Amurensis fruit 55 weight portion Semen Armeniacae Dulcis 105 weight portion Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) 35 weight portion Coixol 25 weight portion nardosinone 7 weight portion megacarpidine 4 weight portions;
Preparation method:
(1) get Semen Armeniacae Dulcis, Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) by crude drug proportioning, mixing, first uses weight percent concentration 90% ethanol as solvent, extract at 55 DEG C of warm macerating, extraction time is 4 times, and each extraction time is 3 hours, each solvent load be Semen Armeniacae Dulcis, 20 times of Central Asia Bletilla striata medicinal materials gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, concentrated, drying, obtains extract A;
(2) Radix Berberidis Amurensis fruit is got by crude drug proportioning, and obtain medicinal residues A with step (1) and mix, be solvent with weight percent concentration 55% ethanol, extract at 70 DEG C of warm macerating, extraction time is 3 times, each extraction time is 3 hours, each solvent load is 15 times of above-mentioned medical material gross weight, filter, extracting solution reclaims ethanol, be concentrated into relative density 1.06, filter, medicinal liquid is by HPD600 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting HPD600 macroporous adsorptive resins of weight percent concentration 75% again, collect weight percent concentration 75% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) get Coixol, nardosinone, megacarpidine by crude drug proportioning, mixing, adds extract A, extract B successively, and mixing, obtains pharmaceutical composition.
Treat a preparation method for the pharmaceutical composition of pulmonary heart disease, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet, capsule, drop pill.
Treat a preparation method for the pharmaceutical composition of pulmonary heart disease, it is characterized in that the treatment pulmonary heart disease medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
The pulmonary hypertension of pharmaceutical composition of the present invention by regulating the dynamic equilibrium of Ang-II and NO, ET-1 content effectively can improve rat, treatment pulmonary heart disease is evident in efficacy.
Detailed description of the invention
Embodiment 1: pharmaceutical composition for the treatment of pulmonary heart disease and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of pulmonary heart disease are:
Radix Berberidis Amurensis fruit 55 weight portion Semen Armeniacae Dulcis 105 weight portion Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) 35 weight portion Coixol 25 weight portion nardosinone 7 weight portion megacarpidine 4 weight portions;
Preparation method:
(1) get Semen Armeniacae Dulcis, Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) by crude drug proportioning, mixing, first uses weight percent concentration 90% ethanol as solvent, extract at 55 DEG C of warm macerating, extraction time is 4 times, and each extraction time is 3 hours, each solvent load be Semen Armeniacae Dulcis, 20 times of Central Asia Bletilla striata medicinal materials gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, concentrated, drying, obtains extract A;
(2) Radix Berberidis Amurensis fruit is got by crude drug proportioning, and obtain medicinal residues A with step (1) and mix, be solvent with weight percent concentration 55% ethanol, extract at 70 DEG C of warm macerating, extraction time is 3 times, each extraction time is 3 hours, each solvent load is 15 times of above-mentioned medical material gross weight, filter, extracting solution reclaims ethanol, be concentrated into relative density 1.06, filter, medicinal liquid is by HPD600 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting HPD600 macroporous adsorptive resins of weight percent concentration 75% again, collect weight percent concentration 75% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) get Coixol, nardosinone, megacarpidine by crude drug proportioning, mixing, adds extract A, extract B successively, and mixing, obtains pharmaceutical composition.
Embodiment 2: pharmaceutical composition for the treatment of pulmonary heart disease and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of pulmonary heart disease are:
Radix Berberidis Amurensis fruit 60 weight portion Semen Armeniacae Dulcis 100 weight portion Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) 40 weight portion Coixol 20 weight portion nardosinone 8 weight portion megacarpidine 3 weight portions;
Preparation method:
(1) get Semen Armeniacae Dulcis, Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) by crude drug proportioning, mixing, first uses weight percent concentration 90% ethanol as solvent, extract at 55 DEG C of warm macerating, extraction time is 4 times, and each extraction time is 3 hours, each solvent load be Semen Armeniacae Dulcis, 20 times of Central Asia Bletilla striata medicinal materials gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, concentrated, drying, obtains extract A;
(2) Radix Berberidis Amurensis fruit is got by crude drug proportioning, and obtain medicinal residues A with step (1) and mix, be solvent with weight percent concentration 55% ethanol, extract at 70 DEG C of warm macerating, extraction time is 3 times, each extraction time is 3 hours, each solvent load is 15 times of above-mentioned medical material gross weight, filter, extracting solution reclaims ethanol, be concentrated into relative density 1.06, filter, medicinal liquid is by HPD600 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting HPD600 macroporous adsorptive resins of weight percent concentration 75% again, collect weight percent concentration 75% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) get Coixol, nardosinone, megacarpidine by crude drug proportioning, mixing, adds extract A, extract B successively, and mixing, obtains pharmaceutical composition.
Embodiment 3: pharmaceutical composition for the treatment of pulmonary heart disease and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of pulmonary heart disease are:
Radix Berberidis Amurensis fruit 50 weight portion Semen Armeniacae Dulcis 110 weight portion Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) 30 weight portion Coixol 30 weight portion nardosinone 6 weight portion megacarpidine 5 weight portions;
Preparation method:
(1) get Semen Armeniacae Dulcis, Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) by crude drug proportioning, mixing, first uses weight percent concentration 90% ethanol as solvent, extract at 55 DEG C of warm macerating, extraction time is 4 times, and each extraction time is 3 hours, each solvent load be Semen Armeniacae Dulcis, 20 times of Central Asia Bletilla striata medicinal materials gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, concentrated, drying, obtains extract A;
(2) Radix Berberidis Amurensis fruit is got by crude drug proportioning, and obtain medicinal residues A with step (1) and mix, be solvent with weight percent concentration 55% ethanol, extract at 70 DEG C of warm macerating, extraction time is 3 times, each extraction time is 3 hours, each solvent load is 15 times of above-mentioned medical material gross weight, filter, extracting solution reclaims ethanol, be concentrated into relative density 1.06, filter, medicinal liquid is by HPD600 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting HPD600 macroporous adsorptive resins of weight percent concentration 75% again, collect weight percent concentration 75% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) get Coixol, nardosinone, megacarpidine by crude drug proportioning, mixing, adds extract A, extract B successively, and mixing, obtains pharmaceutical composition.
Embodiment 4: the preparation of tablet
Example 1 compositions 65g, adds starch 30g, mixing, granulates, dry, adds microcrystalline Cellulose 12g, magnesium stearate 0.5g, and mixing, is pressed into 1000, obtains present composition tablet.
Embodiment 5: the preparation of capsule
Example 2 compositions 65g, adds starch 20g, mixing, granulates, and dry, granulate, adds appropriate magnesium stearate, and mixing, obtains present composition capsule by encapsulated 1000.
Embodiment 6: the preparation of drop pill
Taking polyethylene glycol 6000 100g water-bath (80 DEG C) heating boils molten, add embodiment 3 compositions 10g, stirring, is coolant with liquid paraffin, puts in glass tubing (4*80cm), chilling temperature is 3 DEG C, drip internal-and external diameter is 7.0/2.0 (mm/mm), and drip is 2cm apart from liquid level, drips speed with per minute 50 for optimum condition, blot the condensing agent on drop pill surface with cotton, obtain present composition drop pill.
Embodiment 7: the pharmaceutical composition for the treatment of pulmonary heart disease
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of pulmonary heart disease are:
Radix Berberidis Amurensis fruit 68 weight portion Coixol 20 weight portion nardosinone 6 weight portion megacarpidine 2 weight portions.
Embodiment 8: the pharmaceutical composition for the treatment of pulmonary heart disease
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of pulmonary heart disease are:
Radix Berberidis Amurensis fruit 60 weight portion Coixol 15 weight portion nardosinone 1 weight portion megacarpidine 6 weight portions
Embodiment 9: the pharmaceutical composition for the treatment of pulmonary heart disease
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of pulmonary heart disease are:
Radix Berberidis Amurensis fruit 85 weight portion Coixol 25 weight portion nardosinone 2 weight portion megacarpidine 3 weight portions
Experimental example 1: treatment chronic pulmonary heart disease experimental study
1. clinical data
Meet the diagnostic criteria of the chronic pulmonary heart disease of the 2nd the pulmonary heart disease specialized conference revision in the whole nation in 1997, and eliminating is associated with other cardiovascular diseases such as coronary heart disease, congenital heart disease, rheumatic heart disease and hypertensive heart disease, medicine composite for curing group is totally 23 examples, wherein man 18 example, female 5 example, 60 ~ 80 years old age, average 72 years old, the course of disease is the shortest 3 years, the longest 25 years, average 16 years; Cardiac function carries out classification by NYHA hierarchy plan, wherein IV grade of 8 example, III grade of 12 example, II grade of 3 example; All have that cardiopalmus, dyspnea with rapid and short breath, fullness and distention in the chest and hypochondrium, edema, short urination are in various degree few, face cyanosis of the lips and nails, purplish tongue or dark red; Physical examination is visible: two lung audible and dryness or moist rale, and apex beat has elevating sensation, disperse, and the percussion of heart circle expands, and the side of body is lower can touch liver enlargement, and the hepatojugular reflux positive, lower limbs edema, severe one can have breast, seroperitoneum etc.
2. Therapeutic Method
Matched group gives the Primary Cares such as unimpeded respiratory tract, infection, oxygen therapy, nutritional support according to conditions of patients routine.Treatment group takes embodiment 1 pharmaceutical composition (lot number 20130303) on this basis, every day 3 times, and each 3g, 15d are 1 course for the treatment of.
3. criterion of therapeutical effect
Effective: clinical symptom disappearance, cardiac function improves 2 grades;
Effective: clinical symptoms is obviously improved, cardiac function improves 1 grade;
Invalid: clinical symptoms and cardiac function are without improvement or increase the weight of.
4. therapeutic outcome
The routine patient of medicine composite for curing group 23 all takes medicine 1 course for the treatment of, wherein effective 13 examples, effective 9 examples, and invalid 1 example, total effective rate is 95.65%.
Experimental example 2: on pulmonary heart disease rat ANG-II, NO and ET-1 affect experimental study
1. material
The healthy male Wistar rats 60 of 1.1 animal cleaning grade, weight (250-300) g, by Anhui Province's Experimental Animal Center provide [credit number: SCXK(Anhui) 2011-002.Be divided into matched group, model group and administration group at random, often organize 20.Raise in independent air-feeding isolation cage tool (health is IR60), in cage, temperature controls in (20 ± 1) DEG C, relative humidity 60%.Natural lighting, in plastics cage with wood flour of sterilizing for bedding and padding, drinking water is asked for.
1.2 main agents and instrument 2% pentobarbital; Monocrotaline (lot number: H102017), Sigma Co., USA; Rat Ang-1 II ELISA detection kit, Sigma Co., USA (48T/96T); Rat ET-1ELISA detection kit, Sigma Co., USA (48T/96T); Rat NOELISA detection kit, Sigma Co., USA (48T/96T); Zoopery hypoxia device, Changsha Hua Xi Electronic Science and Technology Co., Ltd.; Animal forced swimming device, fumigation case, The First Affiliated Hospital of Anhui College of Traditional Chinese Medicine; Polygraph, Japanese photoelectricity company; 37C ° of incubator; Wash trigger, general bright DNX-9620; Microplate reader (model: WD-2102A), sample injector, multichannel pipettor; Fructus Mume board medicated cigarette, Hongta Nicotiana tabacum L. group.
2. the method with reference to Li Zegeng, Brown set up by model, copy Disease Syndrome integrated animal model, adaptability raises 1-2 week, rat is put into thermostatic water bath [(0 ± 5) DEG C, dark 35cm] in every day forced swimming 30min, be then placed in 1m3 fumigation case, sootiness every day adds cold air [(0 ± 5) DEG C] 1h, each 20 are gone filter plug Fructus Mume board medicated cigarette (tar content: 13mg, nicotine content: 1.1mg).It is made to feel cold and outer interior impairing the lung sun, simultaneously labor and consume impairing the lung gas.Modeling carries out 6d weekly, within the 7th day, suspends, continuous 3 weeks.Within 4th week, according to ethanol and 0.9% sodium chloride solution (2: 8) mixed liquor, monocrotaline (MCT) is mixed with 1% solution, by 50mg/kg weight lumbar injection 1 time.Gastric infusion after 2 weeks.
3. pharmaceutical intervention administration group gives pharmaceutical composition (embodiment 1 pharmaceutical composition lot number 20110403).Compound concentration is the solution of 0.080g/mL.Above-mentioned concentration presses 1mL100g
-1d
-1the continuous 14d gastric infusion of weight (being equivalent to dose,equivalent of being grown up).Normal group and model group are to 0.9% sodium chloride solution of 2.5mL equivalent.
4. the observing and nursing group of symptom and administration group application fluid-retention in the chest and hypochondrium type (pulmonary heart disease) Chinese medicine syndrome integral carry out syndrome score to rat, observe the severe degree of daytime and cough at night, observe rat purple lip dark purple situation simultaneously, and the severe degree of breathing after rats'swimming.Observing time terminates to administration from modeling, and understanding model group and administration group syndrome integral change.
5. the mensuration row right catheterization of pulmonary arterial pressure in rats measures and often organizes pulmonary arterial pressure in rats.After rat is pressed 10mL/kg intraperitoneal injection of anesthesia with 20g/L pentobarbital, cervical region center is about the stringer otch of 1.5cm, and free right external jugular vein is about 1cm, ligation, clip, with the polyethylene tube (external diameter 0.9mm, internal diameter 0.6mm) of full heparin solution through jugular vein intubate to right ventricle and pulmonary artery.According to monitor, pressure curve waveform judges catheter tip location, with polygraph record pulmonary artery pressure.
The determination experiment of 6.Ang-II, NO, ET-1 content terminates rear abdominal aortic blood, and add in anticoagulant tube and coagulant pipe respectively, the centrifugal 20min of 3000r/min, stand-by at ambient temperature.Utilization ELISA method detects, and detecting step presses the description operation of test kit.
7. statistical method data analysis application SPSS17.0 statistical analysis software, measurement data result all adopts x ± s to represent, compare between two between many groups and carry out variance analysis, during heterogeneity of variance, use Games-Howell method, with P < 0.05 for difference has statistical significance.
8. result
8.1 respectively group rat Chinese medicine syndrome integral and the displays of drug influence laboratory observation, after gastric infusion, cough, the tachypnea of administration group rat all have clear improvement (P < 0.01), Chinese medicine syndrome integral aspect, administration group is totally better than model group (P < 0.01), in Table 1-table 2.
Table 1 model group compares (n=20 divides) with administration group tcm syndrome factor integration
Note: compare with after the modeling of this group,
*p<0.05,
*p<0.01.
The comparison (x ± s, n=20) of two groups of Chinese medicine syndrome integral before and after table 2 administration
Note: compare with after the modeling of this group,
*p<0.01, compares with model group the same period,
△ △p<0.01.
The 8.2 influence research results respectively organizing pulmonary arterial pressure in rats and medicine show, and compare with normal group, after modeling, the pulmonary artery pressure of its model group significantly raises (P < 0.01), show modelling success; Compare with model group, after the administration of administration group, its pulmonary artery pressure obviously reduces (P < 0.01), and it is effective that experimental result shows that pharmaceutical composition improves its pulmonary hypertension for fluid-retention in the chest and hypochondrium type CP, in table 3.
The comparison (x ± s, n=10, mmHg) of pulmonary arterial pressure in rats respectively organized by table 3
| Group | Pulmonary artery pressure |
| Normal group | 13.63±0.86 |
| Model group | 41.27±1.17 * |
| Administration group | 13.78±0.69 **△△ |
Note: compare with normal group,
*p<0.05, compares with model group,
△ △p<0.01.
The change list 4 of 8.3Ang-II and NO, ET-1 content shows, compares with normal group, and model group Ang II and ET-1 content significantly increase, and NO content then obviously reduces (P<0.05).Compare with model group, after the administration of administration group, Ang II and ET-1 content obviously reduce, and NO content then obviously raises (P < 0.01).Illustrate pharmaceutical composition for Ang-II and ET-1, NO content change be effective.
Table 4 is group rat plasma Ang II, NO and ET-1 comparision contents (x ± s, n=10) respectively
| Group | AngⅡ（pg/mL） | NO（μmol/L） | ET（pg/mL） |
| Normal group | 167.87±7.32 | 32.83±0.61 | 135.14±0.36 |
| Model group | 282.65±3.78 * | 16.79±0.53 * | 165.64±3.08 * |
| Administration group | 225.26±7.26 △△ | 26.43±0.60 △△ | 143.411±2.51 △△ |
Note: compare with normal group,
*p<0.05,
△ △p<0.01.
Claims (8)
1. treat a pharmaceutical composition for pulmonary heart disease, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Radix Berberidis Amurensis fruit 50-60 weight portion Semen Armeniacae Dulcis 100-110 weight portion Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) 30-40 weight portion Coixol 20-30 weight portion nardosinone 6-8 weight portion megacarpidine 3-5 weight portion.
2. a kind of pharmaceutical composition for the treatment of pulmonary heart disease according to claim 1, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Radix Berberidis Amurensis fruit 55 weight portion Semen Armeniacae Dulcis 105 weight portion Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) 35 weight portion Coixol 25 weight portion nardosinone 7 weight portion megacarpidine 4 weight portions.
3. a kind of pharmaceutical composition for the treatment of pulmonary heart disease according to claim 1, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet, capsule, drop pill.
4. a kind of pharmaceutical composition for the treatment of pulmonary heart disease according to claim 1, is characterized in that the treatment pulmonary heart disease medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
5. treat a preparation method for the pharmaceutical composition of pulmonary heart disease, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Radix Berberidis Amurensis fruit 50-60 weight portion Semen Armeniacae Dulcis 100-110 weight portion Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) 30-40 weight portion Coixol 20-30 weight portion nardosinone 6-8 weight portion megacarpidine 3-5 weight portion;
Preparation method:
(1) get Semen Armeniacae Dulcis, Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) by crude drug proportioning, mixing, first uses weight percent concentration 90% ethanol as solvent, extract at 55 DEG C of warm macerating, extraction time is 4 times, and each extraction time is 3 hours, each solvent load be Semen Armeniacae Dulcis, 20 times of Central Asia Bletilla striata medicinal materials gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, concentrated, drying, obtains extract A;
(2) Radix Berberidis Amurensis fruit is got by crude drug proportioning, and obtain medicinal residues A with step (1) and mix, be solvent with weight percent concentration 55% ethanol, extract at 70 DEG C of warm macerating, extraction time is 3 times, each extraction time is 3 hours, each solvent load is 15 times of above-mentioned medical material gross weight, filter, extracting solution reclaims ethanol, be concentrated into relative density 1.06, filter, medicinal liquid is by HPD600 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting HPD600 macroporous adsorptive resins of weight percent concentration 75% again, collect weight percent concentration 75% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) get Coixol, nardosinone, megacarpidine by crude drug proportioning, mixing, adds extract A, extract B successively, and mixing, obtains pharmaceutical composition.
6. a kind of preparation method for the treatment of the pharmaceutical composition of pulmonary heart disease according to claim 5, is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Radix Berberidis Amurensis fruit 55 weight portion Semen Armeniacae Dulcis 105 weight portion Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) 35 weight portion Coixol 25 weight portion nardosinone 7 weight portion megacarpidine 4 weight portions;
Preparation method:
(1) get Semen Armeniacae Dulcis, Central Asia Pseudobulbus Bletillae (Rhizoma Bletillae) by crude drug proportioning, mixing, first uses weight percent concentration 90% ethanol as solvent, extract at 55 DEG C of warm macerating, extraction time is 4 times, and each extraction time is 3 hours, each solvent load be Semen Armeniacae Dulcis, 20 times of Central Asia Bletilla striata medicinal materials gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, concentrated, drying, obtains extract A;
(2) Radix Berberidis Amurensis fruit is got by crude drug proportioning, and obtain medicinal residues A with step (1) and mix, be solvent with weight percent concentration 55% ethanol, extract at 70 DEG C of warm macerating, extraction time is 3 times, each extraction time is 3 hours, each solvent load is 15 times of above-mentioned medical material gross weight, filter, extracting solution reclaims ethanol, be concentrated into relative density 1.06, filter, medicinal liquid is by HPD600 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting HPD600 macroporous adsorptive resins of weight percent concentration 75% again, collect weight percent concentration 75% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) get Coixol, nardosinone, megacarpidine by crude drug proportioning, mixing, adds extract A, extract B successively, and mixing, obtains pharmaceutical composition.
7. a kind of preparation method for the treatment of the pharmaceutical composition of pulmonary heart disease according to claim 5, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet, capsule, drop pill.
8. a kind of preparation method for the treatment of the pharmaceutical composition of pulmonary heart disease according to claim 5, is characterized in that the treatment pulmonary heart disease medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510572029.1A CN105055892A (en) | 2015-09-09 | 2015-09-09 | Pharmaceutical composition for treating pulmonary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510572029.1A CN105055892A (en) | 2015-09-09 | 2015-09-09 | Pharmaceutical composition for treating pulmonary heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105055892A true CN105055892A (en) | 2015-11-18 |
Family
ID=54485569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510572029.1A Withdrawn CN105055892A (en) | 2015-09-09 | 2015-09-09 | Pharmaceutical composition for treating pulmonary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105055892A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106474139A (en) * | 2016-08-28 | 2017-03-08 | 张金凤 | One kind is for paracmastic tablet of pulmonary heart disease and preparation method thereof |
-
2015
- 2015-09-09 CN CN201510572029.1A patent/CN105055892A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106474139A (en) * | 2016-08-28 | 2017-03-08 | 张金凤 | One kind is for paracmastic tablet of pulmonary heart disease and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872227B (en) | Gelan Xinning soft capsule for treating coronary disease and angina and preparation method thereof | |
| CN104815192A (en) | Pharmaceutical composition for treating hypertension and application of pharmaceutical composition | |
| CN102631647A (en) | Chinese patent medicine mixture for treating acute urticaria | |
| CN101780227B (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
| CN103272092A (en) | Huoxiang Zhengqi externally-applied preparation and its preparation method and application | |
| CN108159213A (en) | It is a kind of to be used to treat Chinese medicine composition of coronary heart disease and preparation method thereof | |
| CN1817354B (en) | Injection of manchurian wildginge and astragalus root and its preparing method | |
| CN102028865A (en) | Medicinal composition for relieving cough and reducing sputum and method for preparing same | |
| CN105395600A (en) | Application of cyclocarya paliurus extract in preparing medicine for treating cardiovascular and cerebrovascular diseases | |
| CN109464583A (en) | A kind of anti-inflammatory Chinese traditional composition for animals and its preparation method and application | |
| CN105055892A (en) | Pharmaceutical composition for treating pulmonary heart disease | |
| CN104324261A (en) | Pharmaceutical composition for treating high blood sugar and preparation method of pharmaceutical composition | |
| CN103191243B (en) | Application of medicament composition composed of coptis chinensis and fructus evodiae and preparation method of medicament composition | |
| CN103549072B (en) | Vital energy-benefiting brain-boosting tea and preparation method thereof | |
| CN102068520A (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN105535587A (en) | Traditional Chinese medicinal preparation for treating heart and kidney disharmony type palpitation and insomnia and preparation method of traditional Chinese medicinal preparation | |
| CN105287921A (en) | Medicinal composition for treating gastric cancer and preparation method thereof | |
| CN105168912A (en) | Medicine composition for treating pulmonary heart disease and preparation method thereof | |
| CN101045116B (en) | Traditional Chinese medicine for treating cholecystitis | |
| CN104622987B (en) | A kind of pharmaceutical composition for treating chronic hepatitis liver cirrhosis and application | |
| CN106728828A (en) | A kind of Chinese medicine preparation and its preparation technology for treating coronary heart disease | |
| CN102614461A (en) | Spray for rapidly relieving stenocardia and preparation method thereof | |
| CN102068670B (en) | Chinese medicinal composition for treating hyperlipidemia | |
| CN101152247A (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN105311065A (en) | Application of aleuritopteris argentea extract in preparation of medicines for treating cardiovascular and cerebrovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20151118 |